Genprex

GNPX

Market cap $9.76M

Overview Fund Activity

0.2917 USD

+0.0332

12.84%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

0.2793

-0.0124

4.25%

1 day

12.84%

5 days

-5.38%

1 month

24.39%

3 months

-6.83%

6 months

-15.45%

Year to date

-67.62%

1 year

-32.16%

5 years

-99.8%

10 years

-99.84%

About: Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Employees: 15

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 4

64% more capital invested

Capital invested by funds: $93.5K [Q1] → $153K (+$59.7K) [Q2]

17% more funds holding

Funds holding: 24 [Q1] → 28 (+4) [Q2]

0% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 6

2.11% less ownership

Funds ownership: 4.52% [Q1] → 2.41% (-2.11%) [Q2]

See Fund Rankings

Financial journalist opinion

Genprex to Present and Participate at Upcoming September Investor and Industry Conferences

Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , Sept. 2, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's participation in the following upcoming investor and industry conferences being held in September 2025.

Genprex to Present and Participate at Upcoming September Investor and Industry Conferences

Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers

Strengthens Intellectual Property Estate for REQORSA Oncology Program with Immune Checkpoint Inhibitors AUSTIN, Texas , Aug. 18, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent to Genprex that covers the use of the Company's lead drug candidate, Reqorsa® Gene Therapy, in combination with PD-L1 antibodies, such as Tecentriq®. Similarly, the European Patent Office has issued a Notice of Allowance to Genprex for a patent covering the use of REQORSA in combination with PD-1 antibodies.

Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers

Genprex Issues Stockholder Letter and Provides 2025 Corporate Update

Company Achieves Multiple Clinical Development Milestones in 2025 Patient Treatment Continues in Two Lung Cancer Clinical Trials AUSTIN, Texas , Aug. 4, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has issued a stockholder letter and corporate update summarizing the Company's recent achievements across its oncology and diabetes programs and outlines key milestones for 2025 and beyond. "Genprex has made significant progress across our technology programs this past year, and I am enthusiastic about Genprex's future as we continue to advance our clinical development program while maintaining streamlined, focused strategies that are important to build value across the entire company," said Ryan Confer, President and Chief Executive Officer.

Genprex Issues Stockholder Letter and Provides 2025 Corporate Update

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Latest Research Demonstrates Promising Improved Glucose Homeostasis by Reprogramming Alpha Cells AUSTIN, Texas , June 24, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical research from studies of GPX-002, the Company's diabetes gene therapy drug candidate, at the 2025 American Diabetes Association (ADA) 85th Scientific Session in Chicago. "We are proud of the research presented at the ADA conference, which demonstrates that alpha cells in animal models of T1D have undergone transdifferentiation to beta-like cells after being transduced with GPX-002.

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions

Novel Diabetes Gene Therapy Shows Potential for Re-Dosing Using Non-Viral Delivery System AUSTIN, Texas , June 23, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical data and research from studies of GPX-002, the Company's diabetes gene therapy drug candidate, at the 2025 American Diabetes Association (ADA) 85th Scientific Session in Chicago. These studies used an alternative second-generation approach with a non-viral lipid nanoparticle delivery system.

Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions

Genprex to Participate at BIO 2025 International Convention

AUSTIN, Texas , June 3, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its team will be attending and participating at the BIO 2025 International Convention taking place June 16-19, 2025 in Boston, Mass. In attendance from Genprex's executive leadership team will be Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing.

Genprex to Participate at BIO 2025 International Convention

Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Presentation to Highlight Genprex's Study of Reqorsa® Gene Therapy in Combination with Tecentriq® for the Treatment of Extensive Stage Small Cell Lung Cancer AUSTIN, Texas , May 29, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has been selected to present at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 – June 3 in Chicago, Illinois and online. Genprex's abstract, which is now available on the 2025 ASCO Annual Meeting conference website, was selected for a poster presentation for the Trials in Progress portion of the conference.

Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

Novel Gene Therapy is Addressing Both Type 1 and Type 2 Diabetes AUSTIN, Texas , May 28, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced that its research collaborators presented positive preclinical data and research from studies of GPX-002, the Company's diabetes gene therapy drug candidate, in an oral presentation at the American Society of Gene and Cell Therapy's (ASGCT) 28th Annual Meeting which took place May 13-17, 2025 in New Orleans, Louisiana. "We are pleased with the preclinical studies evaluating our novel gene therapy in diabetes, and we are proud to have been selected to present this data before an audience of innovators in cell and gene therapy," said Ryan Confer, President and Chief Executive Officer at Genprex.

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes

Advances Relationship and Collaboration with the University of Pittsburgh of the Commonwealth System of Higher Education AUSTIN, Texas , May 7, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that following the recent completion of its two-year Sponsored Research Agreement (SRA) with the University of Pittsburgh of the Commonwealth System of Higher Education (Pitt) to study Type 1 diabetes (T1D) and Type 2 diabetes (T2D), the parties have entered into a new SRA to study GPX-002, the Company's gene therapy for diabetes, in T1D and T2D in animal models. "We continue to make advancements in our studies of GPX-002 in both T1D and T2D, including mouse models, construct optimization and studies in other animal models," said Ryan Confer, President and Chief Executive Officer at Genprex.

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes

Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma

License Expands Genprex's Portfolio of Oncology Gene Therapy Technologies AUSTIN, Texas , May 6, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive patent license agreement with UTHealth Houston granting Genprex exclusivity and commercial rights relating to its lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid) for the potential treatment of glioblastoma. The subject patent is co-owned by Genprex and UTHealth Houston, and the license provides Genprex with patent exclusivity.

Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma

See News Rankings

Charts implemented using Lightweight Charts™